SAN DIEGO--(BUSINESS WIRE)--Clarify Medical today announced that the Clarify Home Light Therapy System, the company’s innovative smartphone-connected home phototherapy system, is now covered for Medicare patients with psoriasis, effective immediately. This decision by U.S. Centers for Medicare & Medicaid Services (CMS) falls under its longstanding National Coverage Determination for the treatment of psoriasis, which includes narrowband ultraviolet B (NB-UVB) phototherapy.
The Clarify System, cleared by the FDA in 2017, is indicated for localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology in its published Guidelines of care for the management of psoriasis and psoriatic arthritis. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System’s cloud-based software, enabling patients to administer treatment with clinical precision in the convenience of their homes or while traveling. The connected system monitors dosing, adherence, compliance, patient progress and satisfaction.
The Clarify smartphone app syncs to a patented, lightweight, handheld device which guides patients through delivering targeted narrowband UVB phototherapy treatments for their specific skin conditions. All treatment records, including photographs and patient-reported outcomes, are available to both the patient and the physician and can be used for evaluation during follow-up visits. Clarify CarePartners, trained patient support personnel, act as the first line of support for patients – coaching them on the use of the system and encouraging treatment adherence – greatly reducing the burden of these functions on the physician’s practice.
“This is a significant milestone for Clarify and the patients we serve,” said George Mahaffey, President & CEO of Clarify Medical. “Not only does this decision enable millions of Medicare beneficiaries to treat their psoriasis using the Clarify System, but it also enables the Company to begin establishing coverage with private medical insurance plans, which we are already pursuing in earnest. Our mission now is to make our System accessible and affordable for as many patients as possible.”
Clarify Medical is a private San Diego-based medical device company focused on developing innovative technology, products and services that improve care for people with chronic skin conditions. Its Clarify Home Light Therapy System is now available nationally in the US. Learn more at www.clarifymed.com.
